Value of M2BP in predicting in-stent restenosis in patients after coronary drug-eluting stent implantation

Clin Cardiol. 2022 Mar;45(3):308-314. doi: 10.1002/clc.23775. Epub 2022 Jan 15.

Abstract

Objective: We evaluated the association between plasma levels of mac-2 binding protein (M2BP) with the risk of in-stent restenosis (ISR) after percutaneous coronary intervention (PCI).

Methods: Plasma M2BP levels were compared between 258 patients who experienced ISR at 12-months post-PCI and 258 patients, matched for age and sex, without angiographic evidence of ISR.

Results: The plasma M2BP level was significantly higher in the ISR than in the non-ISR group. On multivariate analysis, adjusted for potential clinical, biochemical, and angiography characteristics, M2BP remained as an independent significant predictor of ISR.

Conclusions: M2BP may be an important predictive biomarker of ISR and may be useful in identifying at-risk patients.

Keywords: in-stent restenosis; inflammation; mac-2 binding protein; migration; proliferation; vascular smooth muscle cells.

MeSH terms

  • Coronary Angiography
  • Coronary Restenosis* / diagnosis
  • Coronary Restenosis* / etiology
  • Drug-Eluting Stents*
  • Humans
  • Percutaneous Coronary Intervention* / adverse effects
  • Risk Factors
  • Stents
  • Treatment Outcome